Generalized Anxiety Disorder

• GABAergic System Dysregulation: The primary mechanistic abnormality involves inadequate GABAergic (gamma-aminobutyric acid) inhibitory neurotransmission in key anxiety circuits. GABA is the brain's major inhibitory neurotransmitter, and reduced GABAergic signaling in the prefrontal cortex, amygdala, and anterior cingulate cortex results in failure to suppress threat-processing responses. This leads to unopposed activation of fear circuits and diminished ability to terminate anxiety responses once initiated. Benzodiazepines work by allosterically enhancing GABA-A receptor chloride channel conductance, providing the basis for their anxiolytic action. Chronic GABAergic insufficiency or receptor density reductions (downregulation) are thought to contribute to the persistent nature of GAD.

• Serotonergic System Hypofunction: The serotonin (5-HT) system modulates emotional regulation through projections from the raphe nuclei to the prefrontal cortex, amygdala, and anterior cingulate. In GAD, reduced serotonergic neurotransmission or receptor dysfunction impairs the brain's ability to regulate worry responses and threat appraisal. Serotonin agonists, particularly selective serotonin reuptake inhibitors (SSRIs) that increase synaptic serotonin via transporter inhibition, are the most effective pharmacological treatment. The therapeutic lag (2-4 weeks for symptom improvement) reflects time required for receptor desensitization and downstream signaling cascade modifications.

• Noradrenergic System Overactivity: The noradrenergic system, originating in the locus coeruleus, mediates arousal and vigilance. In GAD, hyperactive noradrenergic signaling produces excessive physiological arousal, muscle tension, and hypervigilance to threat cues. β-Adrenergic receptor signaling increases cyclic AMP production and enhances cellular excitability. Norepinephrine reuptake inhibitors (like SNRIs) reduce synaptic norepinephrine and are therapeutic. This overactivity provides the mechanistic basis for the physical symptoms of anxiety (tachycardia, diaphoresis, tremor).

• Amygdala Hyperactivation and Prefrontal Hypofunction: Neuroimaging consistently demonstrates exaggerated amygdala response to threat-related stimuli and reduced ventromedial prefrontal cortex (vmPFC) activity in GAD patients. The vmPFC normally suppresses amygdala responses through GABAergic interneurons; reduced vmPFC-amygdala inhibitory signaling permits unchecked amygdaloid threat detection. This creates a system wherein the threat-detection circuit (amygdala) lacks adequate inhibitory "braking," leading to persistent worry and arousal. Functional connectivity abnormalities between the default mode network and salience network further contribute to uncontrolled worry generation.

• Anterior Cingulate Cortex Dysfunction: The anterior cingulate cortex (ACC), critical for attention allocation and error detection, shows abnormal activation patterns in GAD. Hyperactive dorsal ACC activity in response to perceived threat or conflict, combined with reduced ventral ACC activity (which normally promotes adaptive emotion regulation), creates a neural profile favoring persistent worry and threat focus. This underlies the cognitive symptom of difficulty disengaging attention from worry-related content.

• Genetic Factors and Molecular Basis: GAD demonstrates 30-40% heritability, with specific contributions from polymorphisms affecting the COMT gene (catechol-O-methyltransferase, which metabolizes dopamine and norepinephrine) and the BDNF gene (brain-derived neurotrophic factor, essential for neuroplasticity and emotional learning). Reduced BDNF signaling impairs the brain's capacity for extinction learning—the ability to update threat associations and reduce conditioned fear responses. The serotonin transporter promoter polymorphism (5-HTTLPR) shows associations with anxiety vulnerability, particularly in combination with environmental stressors.

• Stress-Induced Hypothalamic-Pituitary-Adrenal (HPA) Axis Dysregulation: Chronic anxiety in GAD involves altered HPA axis function, with elevated cortisol production initially, potentially followed by blunted cortisol responses in chronic cases. Elevated glucocorticoid signaling over prolonged periods causes dendritic atrophy in the hippocampus (impairing extinction memory) and further enhances amygdala reactivity, creating a vicious cycle of sustained anxiety and impaired emotional learning. CRH (corticotropin-releasing hormone) hyperactivity in the amygdala perpetuates anxiety-driven physiological responses.

• Cognitive-Neural Integration: At a systems level, GAD reflects failure of top-down cognitive control mechanisms to suppress bottom-up emotional responses. Weakened connections between the dorsolateral prefrontal cortex (involved in executive function and cognitive reappraisal) and the amygdala permit worry to escalate unchecked. This neurobiological reality explains why reassurance and logical reasoning often fail to relieve anxiety—the affective system outweighs the cognitive system.

• Genetic Predisposition: First-degree relatives of GAD patients have 5-6 times increased lifetime prevalence compared to the general population. Twin studies demonstrate heritability of 30-40%, establishing a strong constitutional basis. Specific polymorphisms in serotonin, GABA, and catecholamine system genes confer vulnerability. Genetic factors alone are insufficient to cause GAD; environmental triggers are requisite for phenotypic expression (diathesis-stress model). This genetic contribution explains why some individuals develop GAD following stressors whereas others exposed to identical stressors do not.

• Early Adverse Life Experiences: Childhood trauma, abuse, and neglect substantially increase GAD risk, particularly through effects on HPA axis programming and amygdala sensitization. Insecure attachment patterns and parental anxiety modeling during childhood increase vulnerability. These experiences alter the normal developmental trajectory of threat-assessment systems and emotion regulation capabilities. The timing of adversity matters; early childhood adversity produces particularly robust effects on anxiety vulnerability.

• Psychosocial Stressors: Significant life stressors (loss, medical illness, financial difficulty, interpersonal conflict) commonly precipitate GAD in genetically vulnerable individuals. Chronic stress maintains and perpetuates anxiety through sustained HPA axis activation and learned patterns of threat hypervigilance. The relationship between stressor severity and GAD onset is not linear; vulnerability factors mediate whether objectively similar stressors produce disorder in different individuals.

• Personality Traits: Neuroticism (the tendency toward negative emotionality, worry-proneness, and threat sensitivity) is the strongest personality predictor of GAD development and persistence. Perfectionism, particularly concerning personal standards, also increases vulnerability. These traits reflect underlying differences in amygdala reactivity and prefrontal regulatory capacity, suggesting that personality and neural function are intimately linked.

• Medical Conditions: Chronic medical illnesses (thyroid disease, cardiac arrhythmias, chronic pain, neurological disorders) frequently coexist with or trigger GAD. The relationship can be bidirectional; chronic illness stressors may precipitate GAD, while GAD-related behavioral changes (avoidance, reduced activity) may worsen medical outcomes. Medical conditions must be ruled out, as they can mimic or exacerbate anxiety symptoms (see Diagnosis section).

• Substance Use and Medication Effects: Caffeine intoxication can precipitate or worsen anxiety symptoms in vulnerable individuals through A2A adenosine receptor antagonism and enhanced noradrenergic activity. Alcohol dependence, stimulant use, and withdrawal from CNS depressants are commonly associated with GAD. Certain medications (corticosteroids, sympathomimetics, some antidepressants early in treatment) can trigger or exacerbate anxiety. Substance use often represents self-medication for underlying anxiety, creating a perpetuating cycle.

• Environmental/Social Factors: Lower socioeconomic status, ethnic discrimination, social isolation, and lack of social support increase GAD risk. These social stressors amplify baseline anxiety vulnerability through chronic HPA axis activation and reduced access to adaptive coping resources. Cultural context influences symptom expression and help-seeking behavior.

• Excessive Worry (Cardinal Symptom): Patients experience persistent, uncontrollable worry about multiple life domains (finances, health, family, work) that is difficult to dismiss and markedly disproportionate to actual threat level. The worry is future-oriented and repetitive. Patients often recognize the worry as excessive but cannot voluntarily stop it, reflecting the dissociation between cognitive and affective brain systems noted in pathophysiology. Worry content often shifts between domains. Unlike obsessions in OCD, GAD worries are not ego-dystonic (patients don't find them intrinsically repugnant) but rather feel personally relevant. The worry produces a cycle: initial worry → physiological arousal → further worry amplification due to misinterpretation of arousal sensations as confirming threat.

• Cognitive Symptoms: Patients demonstrate reduced concentration and attention, difficulty making decisions, mind-going blank during important moments, and diminished memory for recent events. These cognitive effects result from amygdala hyperactivation consuming attentional resources and reduced prefrontal cortex function impairing executive processes. Mental rumination predominates, with repetitive thought patterns attempting (ineffectively) to resolve perceived threats. Catastrophic thinking is common, wherein patients anticipate worst-case scenarios.

• Muscle Tension: Persistent muscle tension, particularly in the neck, shoulders, and lower back, results from sustained sympathetic activation and altered motor control. Patients often report achiness, jaw clenching, and inability to relax musculature. This tension reflects both heightened noradrenergic tone and learned motor patterns of guarding in anticipation of threat.

• Autonomic/Physical Symptoms: Tachycardia, palpitations, and chest discomfort result from increased sympathetic tone and enhanced cardiac β-adrenergic receptor responsiveness. Diaphoresis, tremor, and flushing occur through noradrenergic activation of sweat glands and vascular tone regulation. Dyspnea or sensation of breathlessness reflects both increased respiratory drive and hyperventilation-induced hypocapnia (which paradoxically increases dyspnea sensation). Gastrointestinal symptoms (nausea, diarrhea, abdominal discomfort) occur through serotonergic and parasympathetic nervous system dysregulation. Sleep disturbance (difficulty initiating or maintaining sleep, nonrestorative sleep) results from elevated noradrenergic and arousal-promoting systems preventing sleep onset and maintenance.

• Irritability and Mood Changes: Patients frequently report irritability, especially in response to minor stressors, reflecting amygdala hyperresponsivity and reduced behavioral inhibition. Dysphoria is common, though unlike major depression, the primary complaint remains anxiety rather than depressed mood. This reflects the frequent comorbidity of GAD with depression, wherein shared neurobiological systems (serotonin, GABA) are implicated in both.

• Somatic Symptoms: Some patients emphasize physical rather than psychological symptoms, presenting with complaints of dizziness, numbness, tingling, or feeling "unreal" (depersonalization/derealization). These symptoms result from hyperventilation effects (hypocapnia causing vasoconstriction and paresthesias), vestibular system sensitivity, and dissociative responses to overwhelming anxiety. This presentation pattern increases misattribution to medical causes and delays psychiatric diagnosis.

• Behavioral Manifestations: Avoidance behaviors develop, wherein patients avoid situations, activities, or conversations that provoke anxiety. While less prominent than in phobic disorders, avoidance in GAD can become functionally limiting. Reassurance-seeking behavior is typical, with patients repeatedly seeking reassurance from family, friends, or healthcare providers about health concerns or safety, providing temporary relief that reinforces the behavior.

• Physical Examination Findings: Examination findings are typically non-specific but may include elevated resting heart rate (tachycardia), elevated blood pressure, tremor (particularly fine tremor of outstretched hands), and restlessness. Muscle rigidity or tension in neck and shoulders may be evident. Sweating may be apparent. Patients may appear anxious with fidgeting, difficulty maintaining comfortable eye contact, or rapid speech. However, examination may be entirely normal, particularly in well-controlled cases.

• Clinical Variants: Illness Anxiety Disorder represents a variant wherein worry focuses specifically on having or acquiring serious medical illness, with minimal somatic symptoms present. Somatic Symptom Disorder overlaps with GAD when health-related anxiety is prominent, though the primary focus is on interpreting bodily sensations as dangerous rather than general worry. Adjustment Disorder with Anxiety represents maladaptive anxiety response to an identifiable stressor that resolves when the stressor is removed, distinguishing it from primary GAD's pervasive nature.

• DSM-5 Diagnostic Criteria: The diagnosis requires (1) excessive worry occurring more days than not for ≥6 months about multiple life domains (work, family, finances, health); (2) difficulty controlling the worry; (3) ≥3 of the following symptoms: restlessness, fatigue, concentration difficulty, irritability, muscle tension, or sleep disturbance; (4) clinically significant distress or functional impairment; (5) symptoms not attributable to medical conditions, substance use, or another psychiatric disorder (including other anxiety disorders, mood disorders, psychotic disorders, or neurodevelopmental disorders); (6) symptoms not better explained by another medical condition (e.g., hyperthyroidism, cardiac arrhythmia) or medication effect. The 6-month duration requirement distinguishes GAD from brief anxiety episodes and is critical for board exam precision.

• Clinical History and Assessment: Obtain detailed description of worry content, triggers, frequency, and duration. Assess impact on work, relationships, physical health, and daily functioning. Query onset (typically late adolescence or early adulthood, though can occur later), relationship to stressors, course (usually chronic and relapsing if untreated), and prior treatments. Screen for comorbid psychiatric disorders (depression, substance use, OCD, social phobia) given the 60-70% comorbidity rate with other psychiatric conditions. Ask specifically about suicidality, though GAD alone carries minimal suicide risk (unlike depression). Obtain family history of anxiety, depression, and other psychiatric disorders. Inquire about personality traits predating symptom onset (lifelong worry-proneness, perfectionism, neuroticism).

• Generalized Anxiety Disorder-7 (GAD-7) Scale: This seven-item self-report questionnaire is brief, validated, and widely used in both research and clinical practice. Items assess frequency of anxiety symptoms over the prior 2 weeks using a 0-3 scale (0=not at all, 3=nearly every day). Total scores range from 0-21, with cutoff scores: 5-9 mild, 10-14 moderate, 15+ severe anxiety. The GAD-7 has sensitivity of 89% and specificity of 97% for GAD at a cutoff score of 10. Its primary utility is screening, symptom severity quantification, and monitoring treatment response. Board exams frequently reference the GAD-7, making familiarity essential.

• Hamilton Anxiety Rating Scale (HAM-A): This clinician-administered 14-item scale provides comprehensive anxiety assessment with separate domains for psychic anxiety (worry, tension, fears) and somatic anxiety (physiological symptoms). While more time-intensive than GAD-7, it provides detailed symptom profile. Scores >17 suggest moderate to severe anxiety. HAM-A is commonly used in treatment trials and research.

• Physical Examination and Vital Signs: Obtain baseline vital signs; elevated resting heart rate and blood pressure support anxiety diagnosis. Perform general medical examination to assess for tremor, diaphoresis, and muscle tension. Conduct targeted neurological examination if focal symptoms reported. Examine thyroid if relevant given symptom overlap. Physical examination serves as much to rule out

Before prescribing

• Exclude mimics and destabilizers: check TSH, review caffeine/stimulant use, and screen for alcohol or sedative withdrawal — autonomic hyperarousal from withdrawal is a medical emergency, not GAD. Screen for comorbid major depression and suicidality, and for bipolar disorder before starting an antidepressant (risk of precipitating mania). The USPSTF (2023) recommends screening for anxiety disorders in adults aged 19–64, including pregnant and postpartum patients (Grade B); evidence is insufficient (I statement) for adults ≥65. The GAD-7 is the usual instrument.

First-line therapy (psychotherapy, pharmacotherapy, or both)

• Cognitive behavioral therapy: worry exposure, cognitive restructuring, and relaxation training; retrains top-down prefrontal control over amygdala reactivity, which is why its benefit persists after treatment ends.
• SSRIs: escitalopram (FDA-approved for GAD) or sertraline (widely used off-label for GAD; FDA-approved for other anxiety-spectrum indications). Increasing synaptic serotonin drives postsynaptic receptor adaptation, hence the 2–4 week lag; give an adequate dose for 8–12 weeks before calling it a failure. Start low, go slow — initial serotonergic activation can transiently worsen jitteriness and insomnia. Paroxetine is also FDA-approved for GAD but is more anticholinergic and sedating.
• SNRIs: venlafaxine XR or duloxetine, both FDA-approved for GAD and preferred when comorbid neuropathic pain is present.

Escalation and second-line

• Switch within or across class before augmenting; a second SSRI/SNRI trial is reasonable.
• Buspirone: 5-HT1A partial agonist; non-sedating, no dependence, no abuse liability — but has the same weeks-long onset and is useless as needed.
• Hydroxyzine (H1 antagonist) or pregabalin (α2δ calcium-channel ligand, used off-label in the US) as alternatives.
• Benzodiazepines: lorazepam or clonazepam only as a short-term bridge during the SSRI lag, in patients without substance use disorder, with a planned taper.

Contraindicated or avoided

• Benzodiazepines with opioids: FDA boxed warning for respiratory depression and death; also potentially inappropriate in older adults per the AGS Beers Criteria (falls, delirium).
• SSRI/SNRI plus MAOI: serotonin syndrome; requires washout (longer for fluoxetine).
• Paroxetine in pregnancy: ACOG advises avoiding it given the fetal cardiac malformation signal; sertraline is generally preferred.
• There is no surgical or procedural management for GAD.

Complications of the disorder

• Comorbid major depressive disorder: shared serotonergic and HPA-axis dysfunction; signaled by emergence of anhedonia, hopelessness, or neurovegetative change. Most suicide risk in GAD is driven by comorbid depression and substance use disorder, though GAD itself carries some independent increase in risk — always screen directly for suicidal ideation. Active suicidal ideation with plan or intent is an emergency.
• Alcohol, sedative, or benzodiazepine use disorder: self-medication of GABAergic insufficiency; signaled by escalating use, early refill requests, or tolerance.
• Functional and medical morbidity: chronic sympathetic and cortisol elevation contributes to insomnia, tension headache, irritable bowel symptoms, and excess healthcare utilization from repeated cardiac and neurologic workups.

Complications of treatment

• Activation syndrome: early SSRI-induced jitteriness, agitation, and insomnia; paradoxically worsens anxiety in the first weeks and drives nonadherence. Mitigated by low starting doses.
• Serotonin syndrome: excess 5-HT with an added serotonergic agent (MAOI, linezolid, triptan, tramadol); clonus, hyperreflexia, hyperthermia, autonomic instability, lower-extremity predominant. Emergency — stop the agent, cool, benzodiazepines, cyproheptadine.
• Suicidality in patients under 25: FDA boxed warning for all antidepressants; monitor closely early in treatment.
• Hyponatremia/SIADH: SSRI-related, especially in older adults on diuretics; signaled by confusion, lethargy, or a fall. Severe symptomatic hyponatremia is an emergency.
• Bleeding risk: platelet serotonin depletion impairs aggregation; upper GI bleed risk rises with concomitant NSAIDs or anticoagulants.
• Sexual dysfunction and weight change: leading causes of discontinuation.
• Antidepressant discontinuation syndrome: shortest-half-life agents (paroxetine, venlafaxine) — dizziness, flu-like symptoms, electric-shock sensations. Distinguish from relapse by rapid onset after a missed dose.
• Dose-dependent hypertension with venlafaxine; hepatotoxicity is a rare duloxetine concern, particularly with heavy alcohol use.
• Benzodiazepine dependence, falls, and cognitive impairment; abrupt withdrawal causes tremor, autonomic hyperactivity, delirium, and seizures — an emergency requiring reinstitution and slow taper. Buspirone does not treat benzodiazepine withdrawal.

• The duration threshold is the whole question: excessive, hard-to-control worry about multiple domains, more days than not, for ≥6 months, plus ≥3 of six symptoms (restlessness, fatigue, poor concentration, irritability, muscle tension, sleep disturbance). In children only one associated symptom is required.
• Single best next step in a stable outpatient: start an SSRI (escitalopram, sertraline) or SNRI (venlafaxine XR, duloxetine) and refer for CBT. Combination therapy is the highest-yield answer when offered.
• Buspirone is the classic tested drug: 5-HT1A partial agonist, no dependence, no sedation, no respiratory depression, no withdrawal — but a 2–4 week onset, so it is never the answer for acute panic, PRN use, or benzodiazepine withdrawal. Useful when substance use history makes benzodiazepines unsafe.
• Propranolol is the classic distractor: beta blockers blunt peripheral tremor and tachycardia in performance (situational) anxiety, not the cognitive worry of GAD.
• Benzodiazepines are not first-line: short-term bridge only. Avoid in older adults — potentially inappropriate per the AGS Beers Criteria because of falls, fractures, delirium, and cognitive impairment; the well-recognized exception is management of sedative/alcohol withdrawal. Also avoid with opioids (FDA boxed warning) and in patients with substance use disorder.
• The association examiners love: comorbidity. Roughly two-thirds of GAD patients have another psychiatric diagnosis — most often major depression, which drives most of the suicide risk. Always check TSH and caffeine/stimulant intake before anchoring on GAD.
• Screening tool: the GAD-7; USPSTF (2023) recommends anxiety screening in adults aged 19–64, including pregnant and postpartum patients (Grade B), with insufficient evidence (I statement) for adults ≥65. Use it to monitor response, not to diagnose.
• Discriminators: panic disorder = discrete, minutes-long attacks with fear of recurrence; adjustment disorder = identifiable stressor, <6 months, resolves with removal; OCD = ego-dystonic intrusive thoughts with compulsions; illness anxiety disorder = worry confined to having disease with minimal somatic symptoms.
• If a patient "fails" an SSRI at 2 weeks, the answer is usually to continue and optimize the dose — the therapeutic lag reflects receptor adaptation, and an adequate trial runs 8–12 weeks.